Radiologists routinely evaluate for tumor thrombus in the portal and hepatic veins in patients with hepatocellular carcinoma and in the renal vein and inferior vena cava in patients with renal cell carcinoma. However, tumor thrombus occurs in association with numerous other tumor types, . colorectal carcinoma and pancreatic neuroendocrine tumor. Furthermore tumor thrombi are not limited to the primary tumor but also seen with local recurrence and metastatic disease. While less recognized, these thrombi nevertheless affect patterns of recurrence and prognosis. Their detection is critical for accurate local staging and early detection of local recurrence and metastatic disease. The purpose of this pictorial review is to draw the attention of radiologists to the less familiar manifestations of tumor thrombus, review the imaging findings and illustrate the clinical significance of these thrombi.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592090PMC
http://dx.doi.org/10.1259/bjr.20180478DOI Listing

Publication Analysis

Top Keywords

tumor thrombus
16
metastatic disease
12
tumor
8
renal cell
8
local recurrence
8
recurrence metastatic
8
thrombus venous
4
venous drainage
4
drainage pathways
4
pathways primary
4

Similar Publications

Background: Techniques involving dye injection or regional ischemia are commonly used for the precise identification of liver regions during hepatectomy. The visualization of regions with indocyanine green (ICG) has been widely used for liver segmentation. ICG is typically administered only once during each hepatectomy.

View Article and Find Full Text PDF

Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study.

J Gastroenterol Hepatol

December 2024

Department of Surgery, The Research Institute for Transplantation, College of Medicine, Yonsei University, Seoul, South Korea.

Background: Living donor liver transplantation (LDLT) offers timely curative treatment for unresectable hepatocellular carcinoma (HCC). This study aims to validate and compare previous prediction models for HCC outcomes in 488 LDLT recipients.

Methods: For 488 patients who underwent LDLT for HCC, pretransplant imaging studies assessed by modified RECSIT criteria, tumor markers such as alpha feto-protein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA II), and explant pathology were recruited.

View Article and Find Full Text PDF
Article Synopsis
  • Primary liver cancer, mainly hepatocellular carcinoma (HCC), is a major cause of cancer deaths, and tumor thrombus (TT) in major vessels worsens patient outcomes.
  • Four male HCC patients (average age 57) with TT in the inferior vena cava or right atrium underwent surgery to remove the tumors, followed by targeted and immunotherapy.
  • All cases show positive outcomes post-treatment, with some patients remaining disease-free for up to 74 months, suggesting that combining surgery with therapy could improve survival rates in advanced HCC patients.
View Article and Find Full Text PDF

Hepatic artery pseudoaneurysm-the Mayo Clinic experience and literature review.

Front Med (Lausanne)

December 2024

Department of Hospital Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.

Introduction: Hepatic artery pseudoaneurysm (HAP) is a rare and potentially life-threatening condition associated with high mortality. This study aims to review the etiology, clinical manifestations, management, and outcomes of patients diagnosed and treated for HAP at the Mayo Clinic.

Methodology: This study was a retrospective chart review of medical records for patients diagnosed and treated for hepatic artery pseudoaneurysm (HAP) at the Mayo Clinic (Florida, Minnesota, and Arizona) between September 1, 1998, and June 30, 2022.

View Article and Find Full Text PDF

renal transplant carcinoma, especially in the context of bilateral renal carcinoma, is rare and often presents as small, low-grade papillary renal cell carcinoma (RCC). There is currently no consensus or effective treatment for advanced metastatic RCC after kidney transplantation. A 40-year-old man developed renal transplant carcinoma with venous thrombus and lung metastases 13 years after transplantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!